Mandating h1n1 vaccine
Obesity was assigned if indicated in the patient’s medical chart or if the BMI was 30.
The category “no known condition” indicates that the patient did not have any known underlying medical condition indicated in the medical chart at the time of hospitalization.
For the 2017–2018 season, IIV will be available for intramuscular (IM) injection in both trivalent (IIV3) and quadrivalent (IIV4) formulations. The available IIV formulations and age groups for which use is approved are presented in Table 4.
Quadrivalent live attenuated influenza vaccine (LAIV4) is not recommended for use in any setting in the United States during the 2017–2018 influenza season.
This interim recommendation, originally made in 2016, followed observational data from the US Influenza Vaccine Effectiveness Network revealing that LAIV4 performed poorly against influenza A (H1N1)pdm09 viruses in recent influenza seasons;4.
The 2017–2018 influenza A (H1N1) vaccine strain differs from that contained in the 2016–2017 seasonal vaccines.
The 2017–2018 influenza A (H3N2) vaccine strain and influenza B vaccine strains included in the trivalent and quadrivalent vaccines are the same as those contained in the 2016–2017 seasonal vaccines: a.